Vectus Biosystems Ltd
Research Vectus Biosystems Ltd (VBS) on Bullrun: market cap AUD 7.46M, P/E 4.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVBS
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 7.46M
- P/E4.0
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 7.46M; P/E is 4.0.
Peer valuation comparison
Latest P/E is 4x versus a Healthcare sector median of 24.6x (83.7% below).
Latest P/E is 4x versus a Australia median of 15.64x (74.4% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.03 | n/a | n/a | n/a |
| FY2024 | n/a | -AUD 2.34M | -AUD 2.10M | n/a | -0.04 | AUD 808.97K | AUD 28.93K | AUD 1.49M |
| FY2023 | n/a | -AUD 3.45M | -AUD 2.37M | n/a | -0.07 | AUD 2.95M | AUD 70.21K | AUD 3.52M |
| FY2022 | n/a | -AUD 3.99M | -AUD 4.46M | n/a | -0.12 | AUD 1.28M | AUD 6.02M | -AUD 3.53M |
| FY2021 | AUD 180 | -AUD 4.28M | -AUD 3.26M | 100.0% | n/a | AUD 5.78M | AUD 7.67M | -AUD 2.82M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-27 | AUD 7.46M | 4.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based in Rosebery, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vectus Biosystems Ltd's market cap?
Vectus Biosystems Ltd's market capitalization is AUD 7.46M.
What is Vectus Biosystems Ltd's P/E ratio?
Vectus Biosystems Ltd's price-to-earnings (P/E) ratio is 4.0.
What does Vectus Biosystems Ltd do?
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based in Rosebery, Australia.